Dermatan sulfate: Difference between revisions

| CAS_number_Ref = {{cascite|correct|??CAS}}

It is also referred to as [[chondroitin sulfate|chondroitin sulfate B]],<ref name = "Trowbridge_2002">{{cite journal | vauthors = Trowbridge JM, Gallo RL | title = Dermatan sulfate: new functions from an old glycosaminoglycan | journal = Glycobiology | volume = 12 | issue = 9 | pages = 117R–25R117R–125R | date = September 2002 | pmid = 12213784 | doi = 10.1093/glycob/cwf066 | doi-access = free }}</ref> although it is no longer classified as a form of chondroitin sulfate by most sources. The formula is C₁₄H₂₁NO₁₅S. This carbohydrate is composed of linear polymers of disaccharide units that contain, [[N-acetyl galactosamine]] (GalNAc) and [[iduronic acid]] (IdoA). These repeating units are sulfated at a variety of positions.<ref>{{Cite web|url=https://pubchem.ncbi.nlm.nih.gov/compound/Dermatan-sulfate|title = Dermatan sulfate}}</ref> Dermatan sulfate is a component of the compound [[sulodexide]].<ref name="Lasierra-Cirujeda 2010">{{cite journal | vauthors = Lasierra-Cirujeda J, Coronel P, Aza M, Gimeno M | title = Use of sulodexide in patients with peripheral vascular disease | journal = Journal of Blood Medicine | volume = 1 | pages = 105–115 | date = 2010 | pmid = 22282689 | pmc = 3262318 | doi = 10.2147/JBM.S10558 | quote = Sulodexide is a highly purified glycosaminoglycan (GAG) obtained from porcine digestive mucosa and is composed of a mixture of 80% heparan sulfate (an electrophoretically fast moving fraction with a low molecular weight of 7000 Da and affinity for antithrombin III) and 20% dermatan sulfate with a high molecular weight (25,000 Da) and affinity for the heparin II cofactor. | doi-access = free }}</ref>

Dermatan sulfate may have roles in [[coagulation]], [[cardiovascular disease]], [[carcinogenesis]], [[infection]], [[wound repair]], maintainsmaintaining the shape of galactosamine 4-sulfate, skin, and [[fibrosis]].<ref name = "Trowbridge_2002" />

An excess of dermatan sulfate in the [[mitral valve]] is characteristic of myxomatous degeneration of the leaflets leading to redundancy of valve [[tissue (biology)|tissue]] and ultimately, [[mitral valve prolapse]] (into the [[left atrium]]) and insufficiency. This chronic prolapse occurs mainly in women over the age of 60, and can predispose the [[patient]] to [[mitral annular calcification]]. [[Mitral insufficiency|Mitral valve insufficiency]] can lead to eccentric (volume dependent or dilated) [[Hypertrophic cardiomyopathy|hypertrophy]] and eventually [[left heart]] failure if untreated.